A Phase 1, Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2012
At a glance
- Drugs Tivozanib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastrointestinal cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AVEO Oncology
- 04 Jun 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.